Revolution Medicines: Pivotal Trial Readouts Coming, And Buyout Rumors Churning [Seeking Alpha]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Seeking Alpha
Key catalysts include upcoming phase 3 readouts for daraxonrasib in pancreatic cancer (RASolute 302/304), and Breakthrough Therapy designation for zoldonrasib in NSCLC. Buyout rumors have fueled recent price surges, yet reliance on acquisition as a thesis is risky given ephemeral deal chatter and high current expectations. I maintain a hold rating on RVMD, citing outsized near-term correction risks, intense competition, and the need for pivotal clinical/regulatory wins to support current valuation. Klaus Vedfelt/DigitalVision via Getty Images Top Line Summary and Update I don't think you would know it to read the headlines of my coverage of Revolution Medicines, Inc. ( RVMD ), but I am a real optimist about this This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines (NASDAQ:RVMD) was given a new $143.00 price target on by analysts at Mizuho.MarketBeat
- JPM 26: Day 1 – drug prices and policy changes drive the agenda [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines declines to comment on M&A speculation at conference [Seeking Alpha]Seeking Alpha
- JPM26: Eli Lilly reportedly eyes €15bn takeover of Abivax [Yahoo! Finance]Yahoo! Finance
- AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/7/26 - Form 144
- RVMD's page on the SEC website